StockData
Fulcrum Therapeutics, Inc. logo

Fulcrum Therapeutics, Inc. (FULC) stock

FULCNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 12, 2026Score 8/30
$3.69−0.02 (-0.54%)

Close on Nov 20, 2026Market cap $281.54MP/E –Yield –

Fulcrum Therapeutics gross profit

Gross profit is revenue minus the direct cost of the goods and services sold.

No gross profit figures for Fulcrum Therapeutics

Fulcrum Therapeutics has not reported this figure in its SEC filings, or the share price needed to calculate it is not available yet.

More Fulcrum Therapeutics figures

See a number that looks wrong?